Based on these data, a 10 mg/kg dose has been recommended for a phase 2a study of imalumab in combination with 5-FU/Leucovorin or Panitumumab versus standard of care treatment in subjects with mCRC. Patient recruitment for this study is currently ongoing (ClinicalTrials.gov Identifier: NCT...
Assessment of suicide risk in individuals with severe mental illness is currently inconsistent, and based on clinical decision-making with or without tools developed for other purposes. We aimed to develop and validate a predictive model for suicide using data from linked population-based registers in...
The first generation anti-oxMIF antibody imalumab (synonyms: BAX69, BaxB01) demonstrated promising results in a phase I clinical trial with an acceptable safety profile [19]. However, imalumab showed an unusually short half-life in patients, increased aggregation propensity, and an unfavorable ph...
TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT01686802 . 2017 Canadian Medical Association or its licensors.doi:10.1503/cmaj.170017Poonai, NaveenDatoo, NatashaAli, SaminaCashin, MeganDrendel...
Increased risk of intracranial hemorrhage (ICH) complicating microcatheter contrast injections has recently been reported in the second Interventional Management of Stroke (IMS 2) trial with contras...